שווי פעילות לרווח לפני ריבית, מסים ופחת Vericel Corporation (VCEL)

Vericel Corporation management controls the production of cellular products at its plants, delegating delivery to express couriers. The GURU.Markets service reports the company's current EV/EBITDA multiple, which stands at 73.37. This reflects its leadership in cartilage and burn therapies with high FCF, as well as the use of climate control during the transport of living tissues to ensure surgical success.

High-margin sales of MACI and Epicel cell therapies form the operational base of Vericel Corporation (VCEL), determining its fundamental value. This indicator correlates the enterprise value (EV) with earnings before interest, taxes, depreciation, and amortization (EBITDA), allowing for an assessment of the real value of assets without distortions from debt load, which makes the EV/EBITDA chart a key tool for identifying trend reversal points.